Results 81 to 90 of about 11,874 (152)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US

ClinicoEconomics and Outcomes Research, 2013
Machaon M Bonafede,1 Barbara H Johnson,1 Crystal Watson2 1Truven Health Analytics, Cambridge, MA, USA; 2Biogen Idec, Weston, MA, USA Objectives: To evaluate multiple sclerosis (MS)-related health care-resource utilization and costs prior to and after ...
Bonafede MM, Johnson BH, Watson C
doaj  

Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab: An Immunohistochemical Cohort Study. [PDF]

Neurol Neuroimmunol Neuroinflamm
Raabe BS, Stork L, Kutllovci A, Goelz SE, Metz I.   +4 more
europepmc   +1 more source

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years. [PDF]

J Neurol Neurosurg Psychiatry
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, Sun Z, Lasky T, TOP Investigators.   +8 more
europepmc   +1 more source

Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. [PDF]

J Neurol
Muñoz-Vendrell A, Arroyo-Pereiro P, León I, Bau L, Matas E, Romero-Pinel L, Roca-Pereira S, Martínez-Yélamos A, Martínez-Yélamos S.   +8 more
europepmc   +1 more source

Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review. [PDF]

Cureus
Jangirashvili T, Parthiv O, Shengelia L, Tabeshadze Z, Kontchoshvili A, Waked CA, Tamer RM.   +6 more
europepmc   +1 more source

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. [PDF]

Front Immunol
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, Sellebjerg F.   +7 more
europepmc   +1 more source

Do apelin and ghrelin play a role in multiple sclerosis? The analysis of patients treated with immunomodulatory therapies. [PDF]

Front Immunol
Adamczyk B, Morawiec N, Rakoca M, Sowa A, Sawa K, Adamczyk-Sowa M.   +5 more
europepmc   +1 more source

The wearing-off effect with natalizumab: Back to the drawing board. [PDF]

Neurotherapeutics
Afzal S, Conway DS.
europepmc   +1 more source

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy

ClinicoEconomics and Outcomes Research
Luca Prosperini,1 Lorenzo Pradelli,2 Laura Santoni,3 Daria Perini,3 Salvatore Cottone,4 Marco Vercellino5 1S. Camillo-Forlanini Hospital, Rome, Italy; 2AdRes Health Economics and Outcomes Resources, Turin, Italy; 3Biogen Italia, Milan, Italy; 4Department
Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M   +5 more
doaj  

Trajectories of processing speed in multiple sclerosis across disease-modifying therapies. [PDF]

J Neurol
Guo J, Johansson E, Hillert J, Olsson T, Alfredsson L, Hedström AK.   +5 more
europepmc   +1 more source